Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Core Viewpoint - Hemostemix Inc. has appointed Dr. York Hsiang as a Business Consultant, aiming to enhance its operations in treating patients with severe ischemic conditions through its autologous stem cell therapy, ACP-01 [1][9]. Company Overview - Hemostemix is an autologous stem cell therapy platform company founded in 2003, recognized as a World Economic Forum Technology Pioneer. The company has developed and patented VesCell™ (ACP-01), which has shown significant clinical results in treating various cardiovascular conditions [9]. - The company has completed seven clinical studies involving 318 subjects, with results published in eleven peer-reviewed publications. ACP-01 has demonstrated safety and clinical relevance, particularly for conditions like peripheral arterial disease and chronic limb threatening ischemia [9]. Appointment of Dr. York Hsiang - Dr. Hsiang, a globally respected vascular surgeon and Professor Emeritus at the University of British Columbia, has been appointed as a Business Consultant. His extensive experience in vascular surgery and clinical epidemiology positions him to guide Hemostemix in its strategic initiatives [4][5]. - Dr. Hsiang has previously served as the Principal Investigator for Hemostemix's Phase II clinical trial of ACP-01, reinforcing his credibility in the field [4][9]. Clinical Impact of ACP-01 - ACP-01 is considered a game changer for patients with critical limb threatening ischemia (CTLI), where traditional options often lead to amputation. Dr. Hsiang emphasized that he has not seen a therapy as effective as ACP-01 in his 30 years of medical practice [3][2]. - The Phase II trial results indicated a 0% mortality rate in the studied population, with 83% of patients experiencing wound healing and cessation of pain over a follow-up period of up to 4.5 years [9]. Collaboration with First Nations - Hemostemix is actively engaging with Canada's First Nations to establish healthcare initiatives that respect Indigenous sovereignty and promote local employment and capacity-building [7][8]. - The company aims to create a collaborative business plan that integrates traditional cultural healing methodologies with clinical excellence, positioning First Nations communities as centers of healing [8][11].